# Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can

Source: https://onco.cc/trials/nct06149481/  
OnCo record `nct06149481` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of retifanlimab and nogapendekin alfa inbakicept in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) is a phase 1/2, interventional study registered as NCT06149481 by National Cancer Institute (NCI), with a registry enrolment figure of 60 participants, started 2024-03-26 and due to reach its primary completion in 2027-10-31. Interventions recorded: Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform; N-803; SX-682. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Phase I: Safety profiles of the IO regimens consisting of retifanlimab, TriAdeno vaccine, N-803 (A1), and retifanlimab, TriAdeno vaccine, N-803, SX-682 (A2) in participants with metastatic colorectal cancer; Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC. Colorectal eligibility wording from the registry: "* Participants with histologically confirmed colorectal cancer and evidence of metastatic disease". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06149481
- Phase: 1/2
- Setting: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06149481: https://clinicaltrials.gov/study/NCT06149481

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- drugs: [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/), [Retifanlimab](https://onco.cc/drugs/retifanlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06149481.json